Seeking Alpha·Sep 16, 2026
Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptCoherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Coherus Oncology is currently navigating a high-risk transition from a legacy biosimilar business to a focused oncology pipeline, a shift that has resulted in a dramatic revenue contraction from $91.5M in 2023Q4 to $12.3M in 2026Q1. While management has succes...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.19+24.0% vs -$0.25 | $14M-0.7% vs $14M |
Q2 2026 May 11, 2026 | -$0.25+5.1% vs -$0.26 | $12M-13.4% vs $14M |
Q2 2026 Mar 9, 2026 | -$0.34+4.2% vs -$0.36 | $13M-8.4% vs $14M |
Q4 2025 Nov 6, 2025 | -$0.33-3.1% vs -$0.32 | $12M-17.9% vs $14M |
Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BlackRock Inc. bought a new stake in shares of Coherus Oncology, Inc. (NASDAQ: CHRS) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,003,316 shares of the biotechnology company's stock, valued at approximately $16,805,000. BlackRock Inc. owned about
REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:
– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis to stockholders of record of the Company's common stock as of 5:00 p.m.
Benchmark CHRS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Coherus Oncology, Inc. (CHRS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.26 | $154.24M | -0.87 | -84.2% | -403.8% | -279.1% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — | |
| $19.33 | $6.17B | 87.86 | 8.05% | 5.05% | — | — | |
| $14.37 | $2.51B | 5.53 | -12.73% | 3.26% | 1.42% | — | |
| $56.00 | $8.57B | 20.22 | 87.32% | 55.22% | 72.3% | — | |
| $3.80 | $241.54M | -3.22 | 0.78% | -8.7% | -31.27% | — |
Coherus Oncology, Inc. (CHRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Coherus Oncology, Inc. (CHRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 15, 2026·SEC
Jun 1, 2026·SEC
Get notified when CHRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Coherus Oncology, Inc. (CHRS) stock FAQ — growth, dividends, profitability & financials explained
Coherus Oncology, Inc. (CHRS) reported $50.9M in revenue for fiscal year 2025. This represents a 2582% increase from $1.9M in 2012.
Coherus Oncology, Inc. (CHRS) saw revenue decline by 84.2% over the past year.
Coherus Oncology, Inc. (CHRS) reported a net loss of $131.0M for fiscal year 2025.
Coherus Oncology, Inc. (CHRS) has a return on equity (ROE) of -279.1%. Negative ROE indicates the company is unprofitable.
Coherus Oncology, Inc. (CHRS) had negative free cash flow of $243.9M in fiscal year 2025, likely due to heavy capital investments.
